Page 331 - ebook HCC

GENEV
PROGRAMME
EASL HCC SUMMITHCC SUMMIT
328 PROGRAMME AND ABSTRACTSAND ABSTRACTS GENEVA, SWITZERLANDA, SWITZERLAND EASL 329
328
329
FEBRUAR
FEBRUARY 13 - 16, 2014Y 13 - 16, 2014
Poster Board Number C88
MANAGEMENT OF INTERMEDIATE
STAGE OF HCC: A COMPARISON BETWEEN
CONVENTIONAL AND DRUG-ELUTING
BEADS TACE

Igino Rigato 1 2 3 , Riccardo Patti , Manuela Pastoricchio , Flora Masutti 1 2 3 , In the DEB TACE group no severe side effects were observed: 1) pain never exceeded
4
2
Devis Pascut , Valentina Lanzilotti , Fabio Pozzi , Cristiana Abazia , 7 according to the Numeric Rating Scale (NRS), and successfully treated with minor
1
1 2
2 5
2
Claudio Tiribelli 1 2 3 , Lory S. Croce’ 1 2 3 analgesic drugs; 2) nausea and vomiting was observed in only 6 patients. Conversely in
2
1 FIF (italian liver foundation), medical science department, University of Trieste, the Conventional TACE group, pain was observed in all the patients, always with a value
4
3 Centro clinico Studi Fegato AOUTS, medical science department, FIF over 5 NRS and responsive only to major analgesic drugs (oppioids); nausea and vomiting
(italian liver foundation), Radiologia AOUTS, Trieste, Italy was also recorded in all patients. Of notice average hospitalization was 2 days in the DEB
5
TACE group and 12 days in the Conventionl TACE
Corresponding author’s e-mail: rpatti@units.it
Conclusion: We did not observe significant difference between the two techniques of
treatment regarding the response to treatment or the survival rate. The great difference
Introduction: According to the EASL-EORTC Clinical Practice Guidelines (J Hepatol 2012 was found in the days of hospitalization and frequency and severity of side effects. We
56:908-43), patients affected by Hepatocellular Carcinoma (HCC) at intermediate stage conclude that in patients where the main indication for treatment is the palliation of the
(multinodular asymptomatic tumors without an invasive pattern), are eligible for treatment disease, the choice of a treatment that reduces the stress of the patients (less side effects
with Trans Arterial Chemio Embolization (TACE) and few days in the hospital) must be preferred.
Aims: The aim of this study is to compare the outcome of conventional TACE (using
gelfoam-lipiodol particles) with drug-eluting beads (DEB) TACE in particular to evaluate
side effects and clinical outcome
Methodology: 73 patients affected by HCC were treated with DEB-TACE and compared
CLINICAL POSTER ABSTRACTS stratified according to Child-Pugh, CLIP and BCLC. The response to treatment was CLINICAL POSTER ABSTRACTS
with an historic cohort of 59 patients treated with conventional TACE. In both groups,
doxorubicin was used in association with the embolization particles. Patients were

evaluated by CT scan at 3 months after treatment. Overall survival, side effects and days
of hospitalization were considered.

Results: Overall survival rate in both groups was comparable when the patients were
stratified by either BCLC stage (median±ES: BCLC stage A 33±7 months (m) vs 33±5m
and 27±5 vs 21±2m in stage B), Child Pugh (CP) class (CP A: 31±3m vs 31±4 m; CP B:
28±8m vs 23±4 m) or CLIP classification (CLIP 0 38±7m vs 39±8m) for DEB TACE; CLIP
1 26±4m vs 28±3m; CLIP 2, 21± 4 vs 23±6m). Response rate of treated lesions was
comparable in both groups as previously reported (Varela J hep 2007; Poon Clin gast hep
2007).